Scarica l'app Stockscreener
7.40
5.71%
0.40
Dopo l'orario di chiusura:
7.45
0.05
+0.68%
Phathom Pharmaceuticals Inc Borsa (PHAT) Ultime notizie
Phathom Pharmaceuticals Highlights New Cost-Effectiveness - GlobeNewswire
Form 4 Phathom Pharmaceuticals Inc For: 8 October By Investing.com - Investing.com UK
For tax withholding, Phathom (PHAT) CFO surrenders 13,485 shares at $6.78 each. - Stock Titan
Form 4 Phathom Pharmaceuticals Inc For: 8 October By Investing.com - Investing.com Nigeria
Form 8K Phathom Pharmaceuticals Inc For: 29 September By Investing.com - Investing.com Canada
Phathom Pharmaceuticals begins Phase 3 trial for VOQUEZNA in non-erosive GERD By Investing.com - Investing.com South Africa
Form 8K Phathom Pharmaceuticals Inc For: 29 September By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals begins Phase 3 trial for VOQUEZNA in non-erosive GERD - Investing.com UK
Tarsus Pharmaceuticals, Inc. (TARS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Phathom Pharmaceuticals Initiates Phase 3 Study of VOQUEZNA for As-Needed Treatment of Non-Erosive GERD - Quiver Quantitative
Heartburn medicine taken only when symptoms strike is being tested in a new study. - Stock Titan
Understanding the Setup: (PHAT) and Scalable Risk - Stock Traders Daily
PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival - Yahoo Finance
Phathom at Cantor conference: growth, access and new uses By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals targets gastroenterolog... - Pluang
PHAT Initiates Coverage On Leerink Partners -- Rating Set to Mar - GuruFocus
Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case (NASDAQ:PHAT) - Seeking Alpha
Phathom at Cantor conference: growth, access and new uses By Investing.com - Investing.com Canada
Phathom at Cantor conference: growth, access and new uses - Investing.com
PHAT Looks 63.2% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Leerink Partners Initiates Phathom Pharmaceuticals(PHAT.US) With Hold Rating, Announces Target Price $10 - Moomoo
Leerink Partners Initiates Coverage on Phathom Pharmaceuticals With Market Perform, $10 PT - marketscreener.com
Phathom Pharmaceuticals Stock Price Forecast. Should You Buy PHAT? - StockInvest.us
PHAT stock holds near 9 dollars as Q2 loss narrows and revenue rises - ad-hoc-news.de
PHAT stock trades quietly as Phathom Pharmaceuticals prepares next data releases - ad-hoc-news.de
Price-Driven Insight from (PHAT) for Rule-Based Strategy - Stock Traders Daily
Phathom Pharmaceuticals to present at 2026 Cantor and HCWCO investment conferences - Traders Union
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - finance.yahoo.com
4,525,129 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by BlackRock Inc. - MarketBeat
Phathom Pharmaceuticals Inc. (PHAT) Key Financial Ratios – Valuation, Profitability & More - Value Research
Phathom Pharmaceuticals Inc. (PHAT) Peer Comparison – Compare with Others - Value Research
Hsbc Holdings PLC Purchases Shares of 709,695 Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom (PHAT) Today: Moves 3.14% Higher to $8.87 in the Latest Session; Current Setup: the Session Ends Within the Reported Technical Boundaries at the CloseFibonacci Entry Signals - siam.in
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.2%What's Next? - MarketBeat
3,496,808 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by Carlyle Group Inc. - MarketBeat
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and BioMarin Pharmaceutical (BMRN) - theglobeandmail.com
PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff? - Stocktwits
PHAT Maintains Overweight Rating -- Price Target Lowered to $14 - GuruFocus
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Phathom Pharmaceuticals (PHAT) Advances 4.36% to $9.58, Approaches Key Resistance at $10.06MESA MA - vinanet.vn
Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts - Yahoo Finance
Phathom Pharmaceuticals, Inc. (PHAT) Investigation: Bronstein, Ge - The National Law Review
Phathom Pharmaceuticals, Inc.: Target Price Consensus and Analysts Recommendations | PHAT | US71722W1071 - marketscreener.com
PHAT Holds Near $9.18 as Phathom Pharmaceuticals Consolidates Within Key Trading RangeStop Hunt - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Shareholders to Connect - ACCESS Newswire
Why (PHAT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Hennion & Walsh Asset Management Inc. Has $3.55 Million Stake in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals (PHAT) Edges Higher at $8.57: Support Holds as Resistance LoomsTriangle Correction - dars.gov.et
Phathom Pharmaceuticals, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
3.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):